Epigenetic Reprogramming of Immune Cells: Suplexa Offers Orthogonal and Complementary Technology to Gamma Delta Cells
Time: 12:15 pm
day: Pre-Conference Day
Details:
- SUPLEXA technology is applicable to lymphoid immune cells, conferring upon them a number of anti-tumor functions
- First-generation autologous SUPLEXA cells tested in a first-in-human study demonstrates single-agent activity in multiple solid tumors
- The technology is compatible with a variety of engineering approaches mediated by viral and mRNA vectors
